Angiocrine Bioscience Announces First Patient Dose in Pivotal Phase 3 Clinical Trial of AB-205 in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion Series B funding
SAN DIEGO, March 29, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has received a dose in its registrational Phase 3 study AB-205-301 (E -CELERATE), a multicenter, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 is an investigational intravenous cell therapy product under development for multiple indications.
E-CELERATE was designed to evaluate the efficacy and safety of AB-205 as a treatment for vascular stem cell niches of damaged organs caused by HDT off-target cytotoxicity and to prevent the progression of complications serious multi-organ organs, which can be life-threatening and prolong hospitalization. The United States Food and Drug Administration has granted special regulatory status to AB-205 through the Regenerative Medicine Advanced Therapy and Orphan Drug designations for this indication.
More information about the E-CELERATE trial and participating sites can be found on the National Institute of Health’s ClinicalTrials.gov website – NCT05181540.
“We expect 2022 to be a transformational year at Angiocrine, and we are excited to initiate this pivotal Phase 3 study,” said Paul Finnegan, MD, CEO of Angiocrine. “We look forward to continuing to work with many leading cancer centers in United States as we move towards the final clinical stages of this exciting program. »
Series B Funding
Angiocrine Bioscience recently closed a Series B equity financing led by Cobro Ventures with participation from existing Angiocrine shareholders. The newly raised capital will be used to accelerate Angiocrine’s clinical assets and expand its research pipeline. “We are extremely excited about the potential of Angiocrine’s E-CEL® platform,” said Denis Klinman, MD, PhD, Chief Scientific Officer at Cobro Ventures. “Angiocrine’s approach is truly innovative and has great potential to regenerate tissues that have been injured or damaged by diseases such as degenerative, autoimmune and ischemic diseases, in addition to high-intensity cancer treatments.
AB-205 is an investigational, genetically engineered cell therapy composed of engineered allogeneic human endothelial cells (E-CEL® cells). AB-205 is under development for multiple indications and is currently being studied in a single pivotal Phase 3 registrational trial, designed to assess the efficacy and safety of AB-205 in the treatment of severe multi-organ complications related to systemic and diffuse damage to the vascular stem cell niches of multiple organs sustained during high-dose chemotherapy.
About Serious Toxicities and Complications During High-Dose Chemotherapy (HDT) and Autologous Hematopoietic Cell Transplantation (AHCT)
HDT followed by AHCT is considered standard consolidation therapy to cure patients with failed aggressive systemic lymphoma 1st– initiate chemotherapy and respond to induction of chemotherapy. Although highly effective in eradicating aggressive cancer cells, HDT also causes collateral damage to healthy tissue, which can lead to serious toxicities and serious and costly complications. The rates and severity of complications increase with age, and as a result, many elderly patients are turned away from this potentially curative therapy due to concerns about the risk of complications.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company developing advanced restorative drugs composed of engineered human endothelial cells (E-CEL cells). Angiocrine uses its proprietary E-CEL platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions.
For more information, please contact:
SOURCE Angiocrine Bioscience, Inc.